L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y.J. Kim und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do BMI-defined PCOS phenotypes show distinct 15-year trajectories of insulin resistance, hyperandrogenism, and body composition, and which phenotype shows accelerated metabolic deterioration? Summary answer Obese PCOS showed progressive insulin resistance, hyperandrogenism, and visceral fat gain, whereas lean and normal-weight phenotypes remained metabolically stable over 15 years. What is known already Polycystic ovary syndrome is a heterogeneous disorder with substantial variability in metabolic risk across phenotypes. Insulin resistance and hyperandrogenism are central pathophysiological features and are strongly influenced by adiposity and fat distribution. Cross-sectional studies demonstrate worse metabolic profiles in obese PCOS, but long-term data on within-phenotype trajectories are limited. Body composition, particularly visceral adiposity, independently predicts cardiometabolic disease; however, extended longitudinal studies integrating insulin resistance, androgen indices, and body composition across PCOS phenotypes are scarce. This knowledge gap constrains timing and intensity of phenotype-specific preventive interventions. Study design, size, duration This was a prospective longitudinal observational cohort study conducted from 2010 to 2025 at a university-based reproductive endocrinology clinic. Women with PCOS, diagnosed by Rotterdam criteria, were followed with repeated metabolic and hormonal assessments. A total of 187 women were enrolled and stratified by baseline BMI into lean, normal-weight, and overweight/obese phenotypes. At least three longitudinal assessments were available for 151 women (80.7%) Participants/materials, setting, methods Participants were women aged 16–49 years with PCOS attending a tertiary reproductive endocrinology clinic. Measurements included fasting and postprandial glucose and insulin, HOMA-IR, free androgen index, total and free testosterone, DHEA-S, AMH, LH, FSH, lipids, and HbA1c. Body composition was assessed by bioelectrical impedance, including fat mass, lean mass, visceral fat area, and body-fat percentage. Trajectories by BMI phenotype were analysed using repeated-measures ANOVA, correlation analyses, and multivariable linear regression. Main results and the role of chance Over 15 years, the overweight/obese PCOS phenotype showed significant deterioration in insulin resistance, with mean HOMA-IR increasing from 2.84±0.45 at baseline to 3.68±0.61 at final follow-up (29.6% relative increase, p < 0.001). FAI in this phenotype rose from 8.2±3.1 to 12.4±4.7 (51.2% increase, p < 0.001), and the prevalence of FAI >10 increased from 33% to 67% (p < 0.001). Free testosterone increased from 1.02±0.36 to 1.68±0.51 pg/mL (p = 0.008). In contrast, the normal-weight phenotype (HOMA-IR 2.18±0.38 to 2.29±0.39, p = 0.42; FAI 4.1±2.1 to 4.8±2.4, p = 0.18) and the lean phenotype (HOMA-IR 1.95±0.35 to 2.05±0.37, p = 0.61; FAI 3.2±1.8 to 3.6±1.9, p = 0.51) showed no statistically significant metabolic change. Body-composition analysis demonstrated that obese women had a marked increase in fat mass from 27.4±6.2 kg to 35.2±8.1 kg (p < 0.001), visceral fat area from 98.3±24.5 cm² to 154.3±38.7 cm² (p < 0.001), and body-fat percentage from 38.2±5.1% to 45.3±6.2% (p < 0.001), with a modest decline in lean mass from 45.3±4.8 kg to 43.6±5.1 kg (p = 0.03). Normal-weight and lean phenotypes exhibited minimal body-composition change (all p > 0.05). HOMA-IR change correlated positively with fat-mass gain (r = 0.58, p < 0.001), and visceral adiposity independently predicted HOMA-IR progression (β = 0.041, p = 0.002), indicating that the observed trajectories are unlikely to be explained by chance alone. Limitations, reasons for caution Follow-up intervals were not uniform, and treatment exposure (for example, metformin, oral contraceptives, GLP-1 agonists, lifestyle programmes) was not standardised in this observational prospective cohort study. Bioelectrical impedance, rather than reference methods, assessed body composition. Wider implications of the findings These findings support early, intensive insulin-sensitising and weight-management strategies in obese PCOS to prevent long-term metabolic deterioration, while lean and normal-weight phenotypes may benefit from more targeted, non-metabolic approaches. Integrating serial body-composition assessment with HOMA-IR and FAI can refine phenotype-based risk stratification and guide personalised PCOS management algorithms. Trial registration number No
Zitieren
APA
Kim, Y., Han, H., Oh, Y., Oh, S., & Shin, J. (2026). L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1087
Vancouver
Kim Y, Han H, Oh Y, Oh S, Shin J. L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1087
BibTeX
@article{Kim2026,
author = {Kim, Y.J. and Han, H.J. and Oh, Y.J. and Oh, S.M. and Shin, J.H.},
title = {L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1087}
}
EUVIMED